Latest Market News

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.

H&G High Conviction Limited reported a $2.9 million net loss for FY2025 amid challenging market conditions and completed a major asset sale to Hancock & Gore Limited, marking a pivotal shift in its business model.

AXP Energy has updated its resource disclosures and is accelerating its gas-to-power strategy to fuel bitcoin mining operations in Oklahoma, leveraging proven oil fields and strong industry partnerships.

betr Entertainment Limited has removed a key condition from its takeover offer for PointsBet Holdings, clearing a significant hurdle in the acquisition process. The move signals increased confidence in completing the deal and reshapes the dynamics for PointsBet shareholders and employees.

Cedar Woods Properties has updated its Dividend Reinvestment Plan default to cash payment and announced a fully franked 19-cent dividend for the half-year ending June 2025.

Airtasker Limited is set to release its FY25 financial results on 28 August 2025, accompanied by an investor webinar featuring CEO Tim Fung and CFO Mahendra Tharmarajah. The announcement comes as the company highlights its new partnership with the Visa Cash App Racing Bulls Formula One Team.

Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.

Optiscan Imaging Ltd has launched a fully underwritten $17.75 million entitlement offer to fund clinical trials and regulatory clearances for its medical devices, marking a pivotal step in its transition to a commercial medical device manufacturer.

betr Entertainment Limited has increased its takeover offer for PointsBet shares to 4.375 betr shares per PointsBet share, valuing each at $1.40 and surpassing MIXI’s cash bid. The company also expanded its selective buy-back pool to $90 million, signaling confidence in its acquisition strategy.

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.

Ava Group Limited reported solid FY25 results with 5% revenue growth to $31.7 million and a turnaround to positive EBITDA of $2.1 million, underpinned by strong demand for its Aura Ai-X security solutions and a robust $88 million sales pipeline.

Ava Risk Group reported a 5% revenue increase to $31.7 million in FY2025, achieving a significant turnaround to $2.1 million underlying EBITDA. The company expanded its Aura Ai-X technology into new sectors and regions despite some order delays.